One shot to save sight? gene therapy trial aims to end monthly eye injections

NCT ID NCT05657301

First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 20 times

Summary

This early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment delivers a protein that blocks abnormal blood vessel growth, potentially replacing the need for regular eye injections. About 25 adults aged 50-85 who have previously responded to standard anti-VEGF therapy will receive a single dose to check safety and tolerability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Kanghong Investigative Site

    Phoenix, Arizona, 85016, United States

  • Kanghong Investigative Site

    Lemont, Illinois, 60439, United States

  • Kanghong Investigative Site

    Boston, Massachusetts, 02114, United States

  • Kanghong Investigative Site

    Reno, Nevada, 89502, United States

  • Kanghong Investigative Site

    Cherry Hill, New Jersey, 08034, United States

  • Kanghong Investigative Site

    Germantown, Tennessee, 38138, United States

  • Kanghong Investigative Site

    Dallas, Texas, 75231, United States

Conditions

Explore the condition pages connected to this study.